查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球药品再利用市场，到 2030 年的预测：按类型、治疗领域和地区分類的全球分析
市场调查报告书
商品编码
1372003

全球药品再利用市场，到 2030 年的预测：按类型、治疗领域和地区分類的全球分析

Drug Repurposing Market Forecasts to 2030 - Global Analysis By Type (Target-Centric Approach, Disease-Centric Approach and Drug-Centric Approach), Therapeutic Area and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球药物再利用市场规模为 387 亿美元，预计在预测期内年复合成长率为 7.4%，到 2030 年将达到 639 亿美元。

药物再利用（也称为药物重新定位或药物重新分析）是药物研究和开发中使用的一种技术，其中研究用于治疗一种疾病或病理的现有药物并用于治疗其他疾病。它用于治疗病理。与开发全新药物相比，该策略具有更短的开发时间、更低的成本以及更好地了解药物的安全性等优势。透过研究作用机制、药理学特征以及治疗各种疾病和病症的潜力，研究人员可以发现已核准药物的新治疗用途。

药品短缺和医疗需求未被满足

使用重新调整用途的药物来治疗被忽视的热带疾病 (NTD) 和罕见疾病是非常有益的。开发新药很困难，因为针对这些疾病的研究和开发很少。为该患者族群提供替代疗法的一个可行策略是药物再利用。由于生产问题、产品撤回、供应链中断等原因，某些药品可能会出现短缺。将其他现有药物重新用于类似的适应症可以帮助消除药物短缺并确保持续获得​​救命药物。

智慧财产权保护力道不够

智慧财产权保护不充分或不存在可能会阻碍製药公司和投资者参与药物再利用配合措施。如果没有专属行销权和收益潜力，进行再利用研究的经济诱因就会减少，竞争也会加剧，因为多个组织可能会针对同一种药物进行再利用。多种版本的再利用药物竞争市场占有率，可能会导致市场分散化。

成本和时间效率

开发一种全新的药物，从药物研发到上市核准，可能非常昂贵，有时高达数十亿美元。另一方面，透过利用具有已知安全性的现有物质，药物重复使用可以显着降低研究成本。传统药物开发从研究开始到监管核准可能需要 10 多年的时间。另一方面，拖曳重新利用通常会导致更快的开发时间。研究人员无需将时间花在漫长的早期药物研发过程上，而是可以专注于临床评估和监管核准，节省成本和时间。这将增加该技术的采用并进一步提振市场。

市场竞争

由于激烈的竞争，药物再利用市场可能会变得分散。许多营业单位可能会重复使用相同的药物，因为它效率低、成本高昂，并且会减慢开发过程。这可能会导致重复配合措施、资源分散以及相同药物再利用的临床试验的重复和重复。在竞争激烈的情况下，製药公司、学术机构和研究团体之间的合作可能会受到抑制。这可能会导致资讯、资源和专业知识的共用变得困难，并导致开发缓慢。

COVID-19 的影响

COVID-19大流行迫切需要有效的治疗方法和疫苗接种。由于药物的重新利用，研究人员能够快速研究现有的可能治疗该病毒及其症状的药物。快速反应对于解决公共卫生问题至关重要。重新利用药物治疗 COVID-19 的有效性已成为多项研究的主题。这些研究测试了抗病毒药物、发炎剂和改造疫苗。这些发现对建议和治疗指南具有影响。

以目标为中心的进场领域预计将在预测期内达到最大

由于药物再利用中以标靶为中心的方法侧重于根据与疾病相关的特定分子标靶和途径来发现和创造治疗方法，因此以标靶为中心的方法部分预计将出现良好的增长。此策略首先要了解疾病的生物学原理，然后寻找可以影响已发现的标靶或途径的现有药物或化学物质。以目标为中心的方法可以鉴定疾病生物标记，可用于患者分层、治疗反应监测和疾病进展预测。

预计领域在预测期内将经历最高的年复合成长率

由于这些药物具有经过验证的安全实绩和作用机制，因此预计肿瘤学领域在预测期内将以最高的年复合成长率成长。肿瘤学领域的重新配合措施可以集中在发现与癌症发展和扩散相关的新分子标靶和途径。这可能会导致对可以改变这些目标的现有药物的探索。已经启动了几项临床试验，以确定重新利用的药物是否能有效治疗各种肿瘤。此外，这些研究对于证明新用途药物的有效性和安全性至关重要。一些药物在未能证明其原始适应症的功效后，已被有效地重新用于治疗癌症，为临床使用提供了第二次机会。

比最大的地区

预计北美将在预测期内占据最大的市场占有率，因为它是蓬勃发展的製药业的所在地，并且大型製药企业正在资助药物再利用的研究。这些公司通常拥有长期临床试验和重新利用药物商业化所需的资产和专业知识。合作研究在北美很常见，政府、企业和学术机构经常就重新利用计画进行合作。合作研究有助于调动资源和知识。此外，资金由美国国立卫生美国(NIH) 等美国政府机构提供。这种支持激发了该领域的创造力。

复合年复合成长率最高的地区

预计欧洲在预测期内的年复合成长率最高。这是因为欧洲拥有世界上最大、成长最快的药物再利用市场。对负担得起的药物开发的需求、不断增加的患者数量以及大量的研发支出推动了市场的发展。欧洲拥有多家着名的学术机构、製药公司和研究机构，它们积极致力于药物的再利用。欧洲药品管理局 (EMA) 等欧洲法规机构可以核准再利用药物。该地区有利的药物再法规环境促进了再利用药物的开发和市场开拓。

免费客製化服务

订阅此报告的客户可以利用以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究来源
    • 主要研究来源
    • 二次研究来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球药品再利用市场：依类型

  • 以目标为中心的方法
  • 以疾病为中心的方法
  • 以药物为中心的方法

第6章全球药品再利用市场：依治疗领域

  • 中枢神经系统疾病
  • 肿瘤学
  • 神经退化性疾病
  • 其他治疗领域

第7章全球药品再利用市场：依地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第8章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第9章公司简介

  • Excelra
  • ChemBio Discovery, Inc.
  • Celentyx Ltd
  • Algernon Pharmaceuticals
  • Biovista
  • Lantern Pharma, Inc.
  • Fios Genomics
  • Segue Therapeutics, LLC
  • Paradigm Biopharmaceuticals Ltd
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Sosei Group Corporation
  • Centene Corporation（Health Net LLC）
  • SOM Innovation Biotech SL
  • Recursion Pharmaceuticals Inc.
  • Atomwise Inc.
  • Healx
  • NuMedii Inc.
Product Code: SMRC24059

According to Stratistics MRC, the Global Drug Repurposing Market is accounted for $38.7 billion in 2023 and is expected to reach $63.9 billion by 2030 growing at a CAGR of 7.4% during the forecast period. Drug repurposing, often referred to as drug repositioning or drug reprofiling, is a method used in pharmaceutical research and development whereby already-existing medications that were created to treat one disease or condition are examined and then used to treat other illnesses or conditions. Shorter development times, lower costs, and a better grasp of the drug's safety profile are just a few benefits this strategy has over the creation of totally new pharmaceuticals. By examining the mechanisms of action, pharmacological characteristics, and potential to treat various diseases or ailments, researchers can discover novel therapeutic applications for already approved medications.

Market Dynamics:

Driver:

Drug scarcity and unmet medical needs

Using repurposed medications to treat neglected tropical diseases (NTDs) and unusual diseases is very beneficial. It is difficult to produce new medications for these illnesses since little research and development is frequently given to them. A viable strategy for offering therapy alternatives to these patient populations is medication repurposing. Specific medicine shortages may occasionally occur as a result of production problems, product withdrawal, or supply chain interruptions. Drug shortages can be reduced and sustained access to life-saving medicines can be ensured by repurposing other currently available medications for comparable indications owing to encouraging growth of the market.

Restraint:

Insufficient protection for intellectual property

Pharmaceutical firms and investors can be discouraged from taking part in initiatives at medication repurposing if intellectual property protection is inadequate or non-existent. The financial incentives to do repurposing research decline in the absence of the possibility of exclusive selling rights and revenue and several organizations may target the same medicine for repurposing, increasing rivalry. Multiple versions of repurposed medications may compete for market share, fragmenting the market.

Opportunity:

Cost and time efficiency

A fully new drug's development may be extremely expensive, sometimes costing billions of dollars, from discovery through market approval. On the other side, drug repurposing makes use of already-existing substances with known safety profiles, drastically cutting the cost of research. From beginning research to regulatory clearance, traditional medication development might need more than ten years. Drug repurposing, on the other hand, typically has faster development times. Instead of spending time on the time-consuming early drug discovery process, researchers may concentrate on clinical assessment and regulatory approval which in turn saves coast and time. This leads to increased adoption to this method and further propels the market.

Threat:

Market rivalry

The market for drug repurposing may become fragmented as a result of intense rivalry. Inefficient, expensive, and perhaps slowing down the development process, many entities may target the same medications for repurposing. This can result in duplicated efforts and a spread of resources as well as duplicate or overlapping clinical studies for the same repurposed drug. Collaboration between pharmaceutical corporations, academic institutions, and research groups may be discouraged in highly competitive situations. This may slow down development by making it more difficult to share information, resources, and expertise.

COVID-19 Impact

Effective treatments and vaccinations are urgently needed because to the COVID-19 pandemic. Researchers were able to swiftly examine current medications with the potential to tackle the virus and its symptoms thanks to drug repurposing. In order to resolve the public health situation, an expedited reaction time was essential. The effectiveness of repurposed medications in treating COVID-19 had been the subject of several research investigations. Antivirals, anti-inflammatories, and repurposed vaccinations were all tested in these studies. These studies' findings have an impact on recommendations and treatment guidelines.

The target-centric approach segment is expected to be the largest during the forecast period

The target-centric approach segment is estimated to have a lucrative growth, as target-centric approach in drug repurposing focuses on finding and creating treatments based on specific molecular targets or pathways linked to a disease. In this strategy, the biology of a disease is first understood, and then existing medications or chemicals that can influence the discovered target or pathway are sought for. Target-centric methods can result in the identification of disease biomarkers that can be applied to patient stratification, therapy response monitoring, and disease progression prediction.

The oncology segment is expected to have the highest CAGR during the forecast period

The oncology segment is anticipated to witness the highest CAGR growth during the forecast period, because these medications have proven safety records and modes of action. Oncology repurposing initiatives can concentrate on discovering fresh molecular targets or pathways linked to the emergence and spread of cancer. Exploring already available medications that can modify these targets may result from this. To determine if repurposed medications are effective in treating different tumors, several clinical trials have been launched. Moreover, these studies are crucial for proving the effectiveness and safety of repurposed medications. Some medications have been effectively repurposed for cancer after failing to demonstrate efficacy for their original indications, providing them a second opportunity for clinical usage.

Region with largest share:

North America is projected to hold the largest market share during the forecast period because the pharmaceutical trade in North America is thriving, and leading pharmaceutical firms fund research on drug repurposing. These businesses frequently have the assets and know-how necessary to carry out lengthy clinical trials and commercialize repurposed medications. In North America, collaboration is typical, with government, business, and academic institutions frequently collaborating on repurposing initiatives. Collaboration helps to combine resources and knowledge. Moreover, funding is provided by US government organizations like the National Institutes of Health (NIH). The field's creativity is sparked by this backing.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period; owing to the world's biggest and fastest-growing marketplaces for medication repurposing is found in Europe. The market is fuelled by things like the demand for affordable medication development, an increase in the patient population, and significant expenditure in R&D. There are several notable academic institutions, pharmaceutical firms, and research facilities in Europe that are actively engaged in medication repurposing initiatives. Repurposed medicine approval is made possible by European regulatory organizations like the European Medicines Agency (EMA). The development and market accessibility of repurposed medications are made easier by the region's favourable regulatory environment for drug repurposing.

Key players in the market:

Some of the key players profiled in the Drug Repurposing Market include: Excelra, ChemBio Discovery, Inc., Celentyx Ltd, Algernon Pharmaceuticals, Biovista, Lantern Pharma, Inc., Fios Genomics, Segue Therapeutics, LLC, Paradigm Biopharmaceuticals Ltd, Novartis AG, Teva Pharmaceutical Industries Ltd, Sosei Group Corporation, Centene Corporation (Health Net LLC, SOM Innovation Biotech S.L., Recursion Pharmaceuticals Inc., Atomwise Inc., Healx and NuMedii Inc.

Key Developments:

In October 2023, Novartis present new data from 29 Novartis and investigator-led abstracts at the European Society for Medical Oncology (ESMO) Congress 2023, oncology portfolio and addressing unmet needs of patients diagnosed with some of the most prevalent cancers, including prostate and breast.

In April 2023, Excelra, has acquired BISC Global, a bioinformatics and data analytics consulting company with offices across Europe and the USA.

In April 2023, Biosynex Completes Acquisition of Chembio Diagnostics, Inc., The complementary nature of the technologies and product portfolio as well as the combination of market opportunities will be important growth drivers

Types Covered:

  • Target-Centric Approach
  • Disease-Centric Approach
  • Drug-Centric Approach

Therapeutic Areas Covered:

  • CNS Disorders
  • Oncology
  • Neurodegenerative Diseases
  • Other Therapeutic Areas

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Drug Repurposing Market, By Type

  • 5.1 Introduction
  • 5.2 Target-Centric Approach
  • 5.3 Disease-Centric Approach
  • 5.4 Drug-Centric Approach

6 Global Drug Repurposing Market, By Therapeutic Area

  • 6.1 Introduction
  • 6.2 CNS Disorders
  • 6.3 Oncology
  • 6.4 Neurodegenerative Diseases
  • 6.5 Other Therapeutic Areas

7 Global Drug Repurposing Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Excelra
  • 9.2 ChemBio Discovery, Inc.
  • 9.3 Celentyx Ltd
  • 9.4 Algernon Pharmaceuticals
  • 9.5 Biovista
  • 9.6 Lantern Pharma, Inc.
  • 9.7 Fios Genomics
  • 9.8 Segue Therapeutics, LLC
  • 9.9 Paradigm Biopharmaceuticals Ltd
  • 9.10 Novartis AG
  • 9.11 Teva Pharmaceutical Industries Ltd
  • 9.12 Sosei Group Corporation
  • 9.13 Centene Corporation (Health Net LLC
  • 9.14 SOM Innovation Biotech S.L.
  • 9.15 Recursion Pharmaceuticals Inc.
  • 9.16 Atomwise Inc.
  • 9.17 Healx
  • 9.18 NuMedii Inc.

List of Tables

  • Table 1 Global Drug Repurposing Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Drug Repurposing Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Drug Repurposing Market Outlook, By Target-Centric Approach (2021-2030) ($MN)
  • Table 4 Global Drug Repurposing Market Outlook, By Disease-Centric Approach (2021-2030) ($MN)
  • Table 5 Global Drug Repurposing Market Outlook, By Drug-Centric Approach (2021-2030) ($MN)
  • Table 6 Global Drug Repurposing Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 7 Global Drug Repurposing Market Outlook, By CNS Disorders (2021-2030) ($MN)
  • Table 8 Global Drug Repurposing Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 9 Global Drug Repurposing Market Outlook, By Neurodegenerative Diseases (2021-2030) ($MN)
  • Table 10 Global Drug Repurposing Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 14 North America Drug Repurposing Market Outlook, By Country (2021-2030) ($MN)
  • Table 15 North America Drug Repurposing Market Outlook, By Type (2021-2030) ($MN)
  • Table 16 North America Drug Repurposing Market Outlook, By Target-Centric Approach (2021-2030) ($MN)
  • Table 17 North America Drug Repurposing Market Outlook, By Disease-Centric Approach (2021-2030) ($MN)
  • Table 18 North America Drug Repurposing Market Outlook, By Drug-Centric Approach (2021-2030) ($MN)
  • Table 19 North America Drug Repurposing Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 20 North America Drug Repurposing Market Outlook, By CNS Disorders (2021-2030) ($MN)
  • Table 21 North America Drug Repurposing Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 22 North America Drug Repurposing Market Outlook, By Neurodegenerative Diseases (2021-2030) ($MN)
  • Table 23 North America Drug Repurposing Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 24 Europe Drug Repurposing Market Outlook, By Country (2021-2030) ($MN)
  • Table 25 Europe Drug Repurposing Market Outlook, By Type (2021-2030) ($MN)
  • Table 26 Europe Drug Repurposing Market Outlook, By Target-Centric Approach (2021-2030) ($MN)
  • Table 27 Europe Drug Repurposing Market Outlook, By Disease-Centric Approach (2021-2030) ($MN)
  • Table 28 Europe Drug Repurposing Market Outlook, By Drug-Centric Approach (2021-2030) ($MN)
  • Table 29 Europe Drug Repurposing Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 30 Europe Drug Repurposing Market Outlook, By CNS Disorders (2021-2030) ($MN)
  • Table 31 Europe Drug Repurposing Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 32 Europe Drug Repurposing Market Outlook, By Neurodegenerative Diseases (2021-2030) ($MN)
  • Table 33 Europe Drug Repurposing Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 34 Asia Pacific Drug Repurposing Market Outlook, By Country (2021-2030) ($MN)
  • Table 35 Asia Pacific Drug Repurposing Market Outlook, By Type (2021-2030) ($MN)
  • Table 36 Asia Pacific Drug Repurposing Market Outlook, By Target-Centric Approach (2021-2030) ($MN)
  • Table 37 Asia Pacific Drug Repurposing Market Outlook, By Disease-Centric Approach (2021-2030) ($MN)
  • Table 38 Asia Pacific Drug Repurposing Market Outlook, By Drug-Centric Approach (2021-2030) ($MN)
  • Table 39 Asia Pacific Drug Repurposing Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 40 Asia Pacific Drug Repurposing Market Outlook, By CNS Disorders (2021-2030) ($MN)
  • Table 41 Asia Pacific Drug Repurposing Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 42 Asia Pacific Drug Repurposing Market Outlook, By Neurodegenerative Diseases (2021-2030) ($MN)
  • Table 43 Asia Pacific Drug Repurposing Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 44 South America Drug Repurposing Market Outlook, By Country (2021-2030) ($MN)
  • Table 45 South America Drug Repurposing Market Outlook, By Type (2021-2030) ($MN)
  • Table 46 South America Drug Repurposing Market Outlook, By Target-Centric Approach (2021-2030) ($MN)
  • Table 47 South America Drug Repurposing Market Outlook, By Disease-Centric Approach (2021-2030) ($MN)
  • Table 48 South America Drug Repurposing Market Outlook, By Drug-Centric Approach (2021-2030) ($MN)
  • Table 49 South America Drug Repurposing Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 50 South America Drug Repurposing Market Outlook, By CNS Disorders (2021-2030) ($MN)
  • Table 51 South America Drug Repurposing Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 52 South America Drug Repurposing Market Outlook, By Neurodegenerative Diseases (2021-2030) ($MN)
  • Table 53 South America Drug Repurposing Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 54 Middle East & Africa Drug Repurposing Market Outlook, By Country (2021-2030) ($MN)
  • Table 55 Middle East & Africa Drug Repurposing Market Outlook, By Type (2021-2030) ($MN)
  • Table 56 Middle East & Africa Drug Repurposing Market Outlook, By Target-Centric Approach (2021-2030) ($MN)
  • Table 57 Middle East & Africa Drug Repurposing Market Outlook, By Disease-Centric Approach (2021-2030) ($MN)
  • Table 58 Middle East & Africa Drug Repurposing Market Outlook, By Drug-Centric Approach (2021-2030) ($MN)
  • Table 59 Middle East & Africa Drug Repurposing Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 60 Middle East & Africa Drug Repurposing Market Outlook, By CNS Disorders (2021-2030) ($MN)
  • Table 61 Middle East & Africa Drug Repurposing Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 62 Middle East & Africa Drug Repurposing Market Outlook, By Neurodegenerative Diseases (2021-2030) ($MN)
  • Table 63 Middle East & Africa Drug Repurposing Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)